research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Baricitinib works better in adolescents than adults for treating severe alopecia areata.
research Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
research Safety and Efficacy of Mesotherapy with Placenta Polypeptide Injection for Moderate-to-Severe Sensitive Skin: A Multicenter, Randomized, Controlled Trial
Placenta polypeptide injection is a safe and effective treatment for sensitive skin.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
Baricitinib shows promise for treating alopecia areata with mild side effects.
research Supplementary Figure 2 from Male-Pattern Vertex Baldness Trajectories, Chest Hair Patterns, and Odds of Overall and Aggressive Prostate Cancer
Early baldness and little chest hair may indicate higher prostate cancer risk.
research Comparison of effectiveness of weekly azathioprine pulse (WAP) and betamethasone oral mini pulse (BOMP) in the treatment of moderate to severe alopecia areata
Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
research Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients
Mesalazine showed limited effectiveness in treating children with severe alopecia areata.
research Diagnostic Exercise: Severe Bilaterally Symmetrical Alopecia in a Horse
A horse with severe hair loss was diagnosed with alopecia areata and a yeast infection.
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research High‐dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood
High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.
research Limited Effectiveness of Platelet-Rich-Plasma Treatment on Chronic Severe Alopecia Areata
Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research Efficacy and Safety of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial
Using fractional CO2 laser with halometasone cream works better for chronic hand eczema than just the cream, improving symptoms and quality of life with fewer relapses.